426 related articles for article (PubMed ID: 32822582)
21. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance.
Mishra R; Zokaei Nikoo M; Veeraballi S; Singh A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203655
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
23. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Drozd-Sokołowska J; Mądry K; Barankiewicz J; Kobylińska K; Biecek P; Rytel J; Karakulska-Prystupiuk E; Skwierawska K; Salomon-Perzyński A; Stokłosa T; Basak GW
Chemotherapy; 2023; 68(1):16-22. PubMed ID: 36103840
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
26. Nuclear NAD
Shi X; Jiang Y; Kitano A; Hu T; Murdaugh RL; Li Y; Hoegenauer KA; Chen R; Takahashi K; Nakada D
Sci Adv; 2021 Jul; 7(30):. PubMed ID: 34290089
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Sandhu KS; Dadwal S; Yang D; Mei M; Palmer J; Salhotra A; Al Malki M; Aribi A; Ali H; Khaled S; Forman SJ; Snyder D; Nakamura R; Stein AS; Marcucci G; Aldoss I; Pullarkat V
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e322-e327. PubMed ID: 32866594
[TBL] [Abstract][Full Text] [Related]
28. The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine: A Case Report.
Drozd-Sokolowska J; Mądry K; Siewiorek K; Feliksbrot-Bratosiewicz M; Stokłosa T; Gierej B; Stefaniak A; Paszkowska-Kowalewska M; Sokołowski J; Sankowski B; Basak GW
Chemotherapy; 2022; 67(3):173-177. PubMed ID: 35325891
[TBL] [Abstract][Full Text] [Related]
29. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Loren AW; Gill SI; Porter DL; Babushok DV; Maillard IP; Carroll MP; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Paralkar VR; Bruno XJ; Hwang WT; Margolis D; Pratz KW
Blood Adv; 2022 Jul; 6(13):3997-4005. PubMed ID: 35507945
[TBL] [Abstract][Full Text] [Related]
31. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
[TBL] [Abstract][Full Text] [Related]
34. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
Biochem Pharmacol; 2024 Feb; ():116065. PubMed ID: 38373594
[TBL] [Abstract][Full Text] [Related]
35. Aberrant Lipid Metabolic Signatures in Acute Myeloid Leukemia.
Singh P; Murali R; Shanmugam SG; Thomas S; Scott J; Warrier S; Arfuso F; Dharmarajan A; Gandhirajan RK
Stem Cells; 2024 Mar; 42(3):200-215. PubMed ID: 38167958
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
[TBL] [Abstract][Full Text] [Related]
37. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Aldoss I; Dadwal S; Zhang J; Tegtmeier B; Mei M; Arslan S; Al Malki MM; Salhotra A; Ali H; Aribi A; Sandhu K; Khaled S; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Blood Adv; 2019 Dec; 3(23):4043-4049. PubMed ID: 31816059
[TBL] [Abstract][Full Text] [Related]
38. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation.
Amaya ML; Inguva A; Pei S; Jones C; Krug A; Ye H; Minhajuddin M; Winters A; Furtek SL; Gamboni F; Stevens B; D'Alessandro A; Pollyea DA; Reigan P; Jordan CT
Blood; 2022 Jan; 139(4):584-596. PubMed ID: 34525179
[TBL] [Abstract][Full Text] [Related]
39. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA; Newman EM
Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]